p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential

被引:65
作者
Navone, NM
Labate, ME
Troncoso, P
Pisters, LL
Conti, CJ
Von Eschenbach, AC
Logothetis, CJ
机构
[1] Univ Texas, Md Anderson Canc Ctr, Dept GU Med Oncol, Houston, TX 77030 USA
[2] Univ Texas, Md Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[3] Univ Texas, Md Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA
[4] Univ Texas, Md Anderson Canc Ctr, Div Sci Pk Res, Dept Carcinogenesis, Smithville, TX 78957 USA
关键词
p53; prostate cancer; bone metastases; androgen independent;
D O I
10.1016/S0022-5347(01)62136-0
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: This study was undertaken to establish the pattern of specific p53 gene mutations in prostate cancer within primary tumors and distant metastases. Materials and Methods: We performed polymerase chain reaction-single-strand conformation polymorphism and sequencing analyses of p53 exons 5-8 in DNA extracted from 22 formalin-fixed, paraffin-embedded tissues from 17 patients. Samples fi om three patients included specimens from primary and metastatic sites (paired specimens). Results: G:C-to-A:T transitions were the most common point mutations (64%). Six (55%) of 11 G:C-to-A:T transitions occurred at CPG dinucleotides in five hot-spot codons (175, 245, 248, 273, and 282). Sequencing analysis of the paired samples revealed that two of the three pairs had the same mutation in both. Sequencing analysis of DNA from a different area of one of the primary tumors revealed a different mutation in the p53 gene. Conclusions: Our results suggest that specific p53 mutations participate in the progression of human prostate cancer. These findings support those of others that indicate that the primary cancer is heterogeneous and clonal expansion occurs during the progression of clinically detectable prostate cancer. Our data also imply that p53 mutations at the primary site may be predictive of metastases.
引用
收藏
页码:304 / 308
页数:5
相关论文
共 30 条
[1]  
[Anonymous], UROLOGIC PATHOLOGY
[2]   IMMUNOHISTOCHEMICAL DETERMINATION OF P53 PROTEIN NUCLEAR ACCUMULATION IN PROSTATIC ADENOCARCINOMA [J].
APRIKIAN, AG ;
SARKIS, AS ;
FAIR, WR ;
ZHANG, ZF ;
FUKS, Z ;
CORDONCARDO, C .
JOURNAL OF UROLOGY, 1994, 151 (05) :1276-1280
[3]  
Bauer JJ, 1995, CLIN CANCER RES, V1, P1295
[4]  
BOOKSTEIN R, 1993, CANCER RES, V53, P3369
[5]  
Brooks JD, 1996, CANCER RES, V56, P3814
[6]  
CATALONA WJ, 1994, NEW ENGL J MED, V331, P996
[7]  
CATALONA WJ, 1986, CAMPBELLS UROLOGY, P1463
[8]   IMPLICATIONS OF THE P53 TUMOR-SUPPRESSOR GENE IN CLINICAL ONCOLOGY [J].
CHANG, FJ ;
SYRJANEN, S ;
SYRJANEN, K .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (04) :1009-1022
[9]   FREQUENCY AND CHARACTERIZATION OF P53 MUTATIONS IN PRIMARY AND METASTATIC HUMAN PROSTATE-CANCER [J].
DINJENS, WNM ;
VANDERWEIDEN, MM ;
SCHROEDER, FH ;
BOSMAN, FT ;
TRAPMAN, J .
INTERNATIONAL JOURNAL OF CANCER, 1994, 56 (05) :630-633
[10]  
Eastham JA, 1995, CLIN CANCER RES, V1, P1111